Sequana Medical NV (SEQUA) - Total Liabilities

Latest as of June 2025: €53.74 Million EUR ≈ $62.83 Million USD

Based on the latest financial reports, Sequana Medical NV (SEQUA) has total liabilities worth €53.74 Million EUR (≈ $62.83 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SEQUA cash flow metrics to assess how effectively this company generates cash.

Sequana Medical NV - Total Liabilities Trend (2014–2024)

This chart illustrates how Sequana Medical NV's total liabilities have evolved over time, based on quarterly financial data. See net assets of Sequana Medical NV for net asset value and shareholders' equity analysis.

Sequana Medical NV Competitors by Total Liabilities

The table below lists competitors of Sequana Medical NV ranked by their total liabilities.

Company Country Total Liabilities
Tolins Tyres Ltd
NSE:TOLINS
India Rs468.00 Million
Molinos Juan Semino SA
BA:SEMI
Argentina AR$13.45 Billion
Magnitude International Ltd Ordinary Shares
NASDAQ:MAGH
USA $7.91 Million
Zim Laboratories Limited
NSE:ZIMLAB
India Rs2.19 Billion
Yuasa Battery (Thailand) Public Company Limited
BK:YUASA
Thailand ฿590.10 Million
Davolink Inc.
KQ:340360
Korea ₩31.74 Billion
2S Metal Public Company Limited
BK:2S
Thailand ฿342.86 Million
Panagene Inc
KQ:046210
Korea ₩24.65 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Sequana Medical NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SEQUA company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.69 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sequana Medical NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sequana Medical NV (2014–2024)

The table below shows the annual total liabilities of Sequana Medical NV from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 €54.32 Million
≈ $63.51 Million
+83.73%
2023-12-31 €29.57 Million
≈ $34.57 Million
+4.92%
2022-12-31 €28.18 Million
≈ $32.94 Million
+81.89%
2021-12-31 €15.49 Million
≈ $18.11 Million
+9.87%
2020-12-31 €14.10 Million
≈ $16.49 Million
+67.38%
2019-12-31 €8.42 Million
≈ $9.85 Million
-61.88%
2018-12-31 €22.10 Million
≈ $25.84 Million
+171.85%
2017-12-31 €8.13 Million
≈ $9.50 Million
-22.39%
2016-12-31 €10.48 Million
≈ $12.25 Million
+110.92%
2015-12-31 €4.97 Million
≈ $5.81 Million
+55.52%
2014-12-31 €3.19 Million
≈ $3.73 Million
--

About Sequana Medical NV

BR:SEQUA Belgium Medical Devices
Market Cap
$46.97 Million
€40.18 Million EUR
Market Cap Rank
#22168 Global
#94 in Belgium
Share Price
€0.61
Change (1 day)
+0.00%
52-Week Range
€0.47 - €1.54
All Time High
€11.80
About

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more